Window of opportunity: A new insight into sequential bevacizumab and paclitaxel in two cases of metastatic triple-negative breast cancer

Experimental and Therapeutic Medicine

Volumn 10, Issue 3, 2015, Pages 885-888

  Chen, Dar Ren ^a   Lin, Che ^a,b   Wang, Yu Fen ^a  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Bevacizumab; Metastatic triple negative breast cancer; Paclitaxel; Sequential treatment; Vascular normalization

Indexed keywords

BEVACIZUMAB; PACLITAXEL;

AGED; ARTICLE; BREAST METASTASIS; CANCER GRADING; CANCER STAGING; CASE REPORT; FEMALE; HUMAN; MASTECTOMY; NEUTROPENIA; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; VERY ELDERLY;

EID: 84937703476     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2586     Document Type: Article

References (20)

1. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.
2. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247, 2010.
3. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29: 1252-1260, 2011.
4. Lang I, Brodowicz T, Ryvo L, et al; Central European Cooperative Oncology Group: Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: Interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 14: 125-133, 2013.
5. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V and Rugo HS: RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29: 4286-4293, 2011.
6. Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9: 677-684, 2003.
7. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7: 987-989, 2001.
8. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147, 2004.
9. Vakoc BJ, Lanning RM, Tyrrell JA, et al: Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 15: 1219-1223, 2009.
10. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6: 553-563, 2004.
11. Jain RK: Taming vessels to treat cancer. Sci Am 298: 56-63, 2008.
12. Gianni L, Romieu GH, Lichinitser M, et al: AVEREL: A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for her2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31: 1719-1725, 2013.
13. Miles DW, de Haas SL, Dirix LY, et al: Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108: 1052-1060, 2013.
14. Hegde PS, Jubb AM, Chen D, et al: Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19: 929-937, 2013.
15. Goel S, Duda DG, Xu L, et al: Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071-1121, 2011.
16. Goel S, Wong AH and Jain RK: Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2: a006486, 2012.
17. Giuliano S and Pagès G: Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 95: 1110-1119, 2013.
18. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N and Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765-14770, 1996.
19. Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake D, Hahn OM et al: Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). J Clin Oncol 33 (Suppl): 501, 2015.
20. Bragalone DL (ed): Drug Information Handbook for Oncology. 10th edition. Lexicomp, Hudson, OH, pp501-514, 2012.